DRREDDY vs PGHL: Stock Comparison

Dr Reddys Laboratories Ltd vs Procter & Gamble Health Limited

Live data: 22 July 2026, 3:03 PM IST • Source: NSE and company filings

Dr Reddys Laboratories Ltd is the larger company by market capitalisation. Dr Reddys Laboratories Ltd shows a lower P/E, while Procter & Gamble Health Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Dr Reddys Laboratories Ltd and Procter & Gamble Health Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, DRREDDY is more favourable on 2 of 13 scored metrics and PGHL on 11These counts are context-free and are not an overall rating.

Key Differences

Market Cap
DRREDDY is the larger company
₹98,815 Cr vs ₹11,172 Cr
P/E Ratio
DRREDDY has a lower P/E
24x vs 34.28x
P/B Ratio
DRREDDY has a lower P/B
2.66x vs 21.36x
EPS
PGHL has higher earnings per share
₹196.64 vs ₹51.37
Dividend Yield
PGHL has a higher dividend yield
2.34% vs 0.65%
Revenue Growth (TTM YoY)
PGHL has faster revenue growth
19.1% vs -11.6%
EPS Growth (TTM YoY)
PGHL has faster EPS growth
54.6% vs -86.2%
Qtr Sales Growth
PGHL has stronger quarterly sales growth
19.1% vs -11.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricDRREDDYPGHL
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricDRREDDYPGHL
Live Price₹1,183.9₹6,737
Day Change-1.83%-0.63%
Volume21.26 L4,611
52-Week High₹1,414.9₹6,975
52-Week Low₹1,148.4₹4,707
Distance from 52W High-16.33%-3.41%

Valuation

MetricDRREDDYPGHL
Market Cap₹98,815 Cr₹11,172 Cr
P/E Ratio24x34.28x
P/B Ratio2.66x21.36x
EPS₹51.37₹196.64
Book Value₹452.82₹316.01
Dividend Yield0.65%2.34%

Growth

MetricDRREDDYPGHL
Revenue Growth (TTM YoY)-11.6%19.1%
EPS Growth (TTM YoY)-86.2%54.6%
Qtr Sales Growth-11.5%19.1%
Qtr Profit Growth-86.1%54.6%

Profitability & Leverage

MetricDRREDDYPGHL
ROE11.2%61.6%
ROCE13%83.5%
Net Margin12.76%23.22%
Operating Margin19.2%32.4%
Debt to Equity0.2x0.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricDRREDDYPGHL
Promoter Holding26.63% 0.01 pp0%
FII Holding33.08% 0.12 pp6.33% 0.13 pp
DII Holding30.72% 0.28 pp12.44% 1.23 pp
Public Holding9.33% 0.14 pp29.42% 1.11 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Dr Reddys Laboratories Ltd and Procter & Gamble Health Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.